Somatostatin Omeprazole
Somatostatin Omeprazole - Related Videos
05:31
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
0 Views •
Cited by 7 •
2012
A real-time screening procedure for identifying drugs that interact with G protein-gated inward rectifier K+ (GIRK) channels is described. The assay utilizes membrane potential-sensitive fluorescent dyes to measure GIRK channel activity. This technique is adaptable for use on a number of cell lines.
09:21
Viral-mediated Labeling and Transplantation of Medial Ganglionic Eminence (MGE) Cells for In Vivo Studies
0 Views •
Cited by 35 •
2015
GABAergic cortical interneuron progenitors disperse, develop and synaptically integrate into a host cortex after transplantation. These cells can be easily transduced before transplantation for in vivo studies of genetically modified GABAergic precursors. Here, we show viral labeling techniques to target specific interneuron subgroups using existing Cre lines and Cre-dependent reporters.
11:16
Correlative Light- and Electron Microscopy Using Quantum Dot Nanoparticles
0 Views •
Cited by 12 •
2016
A method is described whereby quantum dot (QD) nanoparticles can be used for correlative immunocytochemical studies of epoxy embedded human pathology tissue. We employ commercial antibody fragment conjugated QDs that are visualized by widefield fluorescence light microscopy and transmission electron microscopy.
09:41
Confocal Imaging of Neuropeptide Y-pHluorin: A Technique to Visualize Insulin Granule Exocytosis in Intact Murine and Human Islets
0 Views •
Cited by 12 •
2017
We describe a protocol for visualization of insulin exocytosis in intact islets using pHluorin, a pH-sensitive green fluorescent protein. Isolated islets are infected with adenovirus encoding pHluorin coupled to the vesicle cargo neuropeptide Y. This allows for the detection of insulin granule fusion events by confocal microscopy.
05:38
Custom-made Microdialysis Probe Design
0 Views •
Cited by 9 •
2015
Microdialysis is a commonly used technique in neuroscience research. Therefore commercial probes are in great demand.In this work a probe assembly is explained in detail to build a reliable, concentric, custom-made microdialysis probe for less than $10.
FAQs
Somatostatin acts broadly by inhibiting the release of several gastrointestinal hormones and by reducing splanchnic blood flow. Omeprazole acts more directly at gastric parietal cells by blocking the H+/K+-ATPase, the proton pump responsible for acid secretion. This distinction separates hormonal and vascular regulation from focused control of gastric acid production.
Lower splanchnic blood flow can influence the local vascular environment of the gastrointestinal tract, which is relevant when clinicians are trying to support control of upper gastrointestinal bleeding. Somatostatin therefore contributes more than secretory suppression alone: its vascular effect complements its inhibition of gastrointestinal hormone release in settings where hemostasis is an important goal.
Omeprazole targets the acid-producing machinery of gastric parietal cells rather than broadly inhibiting gastrointestinal hormone release or altering splanchnic circulation. Blocking the H+/K+-ATPase directly lowers gastric acid secretion. That focused action makes its pharmacologic role especially relevant to acid-related disorders, where gastric acidity is a central therapeutic concern.
Both agents may be relevant, but they address different contributors to the clinical problem. Somatostatin can suppress gastrointestinal secretory activity and reduce splanchnic blood flow, while omeprazole decreases gastric acidity through parietal-cell proton-pump blockade. Their distinct actions help clinicians match treatment to the need for hemostatic support, acid control, or both.
The choice depends on which physiologic process requires the strongest emphasis. Omeprazole offers direct reduction of gastric acid secretion, whereas somatostatin provides broader inhibition of gastrointestinal hormone release along with reduced splanchnic blood flow. Comparing these mechanisms helps distinguish therapy aimed primarily at acid control from an approach addressing wider gastrointestinal secretory activity.
Studies can examine changes in gastric acidity, gastrointestinal secretory activity, hormone release, and splanchnic blood flow, depending on the agent being evaluated. Clinical investigations may also consider symptom relief or support for hemostasis in upper gastrointestinal bleeding. Interpreting these outcomes requires linking each observed effect to the drug’s distinct pharmacologic target.